Payment overview · 2025
General Payments
$812.07
26 reported records · 4 companies
Healthcare provider profile · identity verified
Michelle Li
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FLUSHING, NY · NPI 1932506094
Verified facts
What the public records show
CMS Open Payments records show Michelle Li received $812.07 in general payments during 2025 across 26 reported records.
GlaxoSmithKline, LLC. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $271.65 | 33.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $237.92 | 29.3% | 8 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $171.85 | 21.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $130.65 | 16.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $812.07 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $271.65 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $130.65 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $88.64 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.50 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.28 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.28 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
15 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 584 | 217 |
| Vascepa | Icosapent Ethyl | 322 | 113 |
| Losartan Potassium | Losartan Potassium | 310 | 124 |
| Amlodipine Besylate | Amlodipine Besylate | 257 | 100 |
| Alendronate Sodium | Alendronate Sodium | 183 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 37 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 100 | 46 |
| Metformin Hcl | Metformin Hcl | 96 | 37 |
| Simvastatin | Simvastatin | 96 | 29 |
| Famotidine | Famotidine | 84 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 31 |
| Meloxicam | Meloxicam | 68 | 53 |
| Omeprazole | Omeprazole | 68 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 67 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 42 |
| Ibuprofen | Ibuprofen | 63 | 58 |
| Ammonium Lactate | Ammonium Lactate | 60 | 24 |
| Glipizide Er | Glipizide | 56 | 17 |
| Finasteride | Finasteride | 54 | 20 |
| Jardiance | Empagliflozin | 50 | 18 |
| Naproxen | Naproxen | 49 | 38 |
| Donepezil Hcl | Donepezil Hcl | 48 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 29 |
| Diclofenac Epolamine | Diclofenac Epolamine | 41 | 26 |
| Januvia | Sitagliptin Phosphate | 41 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 14 |
| Meclizine Hcl | Meclizine Hcl | 40 | 30 |
| Icosapent Ethyl | Icosapent Ethyl | 38 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Lisinopril | Lisinopril | 35 | 13 |
| Azelastine Hcl | Azelastine Hcl | 34 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 32 | 18 |
| Amoxicillin | Amoxicillin | 31 | 31 |
| Trazodone Hcl | Trazodone Hcl | 31 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 18 |
| Folic Acid | Folic Acid | 29 | 13 |
| Azithromycin | Azithromycin | 28 | 27 |
| Valsartan | Valsartan | 27 | 13 |
| Gabapentin | Gabapentin | 26 | 13 |
| Hydrocortisone | Hydrocortisone | 26 | 18 |
| Rybelsus | Semaglutide | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 23 | 22 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 22 | 21 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 20 |
| Carvedilol | Carvedilol | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 19 |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 19 | 15 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Eliquis | Apixaban | 16 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | 12 |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $812.07 · 26 records | GlaxoSmithKline, LLC. | CREON, EVENITY, LINZESS, NUCALA, QULIPTA, UBRELVY, VYALEV | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error